X4 Pharmaceuticals (XFOR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

XFOR X4 Pharmaceuticals

Watchlist

0.544
-0.045-7.65%

Close Jul 2 16:00 ET

0.550
+0.006+1.01%

Post 19:58 ET

91.41MMarket Cap-812P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Swayampakula Ramakanth maintains $X4 Pharmaceuticals(XFOR.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rat
Moomoo NewsJun 28 06:33 ET · Ratings
X4 Slips After Mid-stage Data for Lead Drug in Neutropenia
Seeking AlphaJun 27 13:40 ET
X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment
X4 Pharmaceuticals (XFOR) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic neutropen
MT NewswiresJun 27 10:44 ET
Express News | X4 Pharmaceuticals Shares Are Trading Lower. The Company Announced Clinical Data From Its Ongoing Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Mavorixafor for the Treatment of People With Chronic Neutropenia
BenzingaJun 27 08:58 ET
Express News | X4 Pharmaceuticals: Screening Patients for Enrollment Into 4Ward Study
ReutersJun 27 06:31 ET
Express News | X4 Pharmaceuticals: Durable Mean Anc Levels Above Lower Limit of Normal for Cn Achieved for Participants on Mavorixafor Monotherapy at Months 3 and 6
ReutersJun 27 06:30 ET

Comments

70686049

Jun 28 09:02

$X4 Pharmaceuticals(XFOR.US)$ so cheap rn

Green Bean Sprouting

Jun 27 09:47

$X4 Pharmaceuticals(XFOR.US)$
holy shit

Trytosaveabit

Jun 27 05:35

Update

$X4 Pharmaceuticals(XFOR.US)$ X4 Pharmaceuticals Inc: 100% Of Evaluable Participants at Month 6 Achieved Target Absolute Neutrophil Count (Anc) Increase

Jaguar8

May 29 15:31

NEWS

$X4 Pharmaceuticals(XFOR.US)$
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
X4 Pharmaceuticals (Nasdaq: XFOR) will host a virtual investor event on June 27, 2024, at 8:00 AM ET to present new interim results from a Phase 2 clinical trial on mavorixafor for treating chronic neutropenia (CN).
The webcast will showcase hematological data from at least 15 participants, treated either wi...